CBS 2019
CBSMD教育中心
中 文

Percutaneous LAA Occlusion

Abstract

Recommended Article

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation: A Cohort Study Impact of left atrial appendage closure on circulating microvesicles levels: The MICROPLUG study Early Rhythm-Control Therapy in Patients with Atrial Fibrillation Detection of Device-Related Thrombosis Following Left Atrial Appendage Occlusion A Comparison Between Cardiac Computed Tomography and Transesophageal Echocardiography​: A Comparison Between Cardiac Computed Tomography and Transesophageal Echocardiography Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes
|<< 1 2 3 4 5 6 >>|

Original Research12 October 2021

JOURNAL：Ann Intern Med. Article Link

Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study

AB Ingason, JP Hreinsson, ES Björnsson et al. Keywords: rivaroxaban vs DOAC; AF; gastrointestinal bleeding

ABSTRACT

BACKGROUND - Gastrointestinal bleeding (GIB) rates for direct oral anticoagulants (DOACs) and warfarin have been extensively compared. However, population-based studies comparing GIB rates among different DOACs are limited.


OBJECTIVE - To compare rates of GIB among apixaban, dabigatran, and rivaroxaban.


DESIGN - Nationwide population-based cohort study.


SETTING - Landspítali–The National University Hospital of Iceland and the 4 regional hospitals in Iceland.


PATIENTS - New users of apixaban, dabigatran, and rivaroxaban from 2014 to 2019.


MEASUREMENTS - Rates of GIB were compared using inverse probability weighting, Kaplan–Meier survival estimates, and Cox regression.


RESULTS - In total, 2157 patients receiving apixaban, 494 patients receiving dabigatran, and 3217 patients receiving rivaroxaban were compared. For all patients, rivaroxaban had higher overall rates of GIB (3.2 vs. 2.5 events per 100 person-years; hazard ratio [HR], 1.42 [95% CI, 1.04 to 1.93]) and major GIB (1.9 vs. 1.4 events per 100 person-years; HR, 1.50 [CI, 1.00 to 2.24]) compared with apixaban. Rivaroxaban also had higher GIB rates than dabigatran, with similar point estimates, although the CIs were wider and included the possibility of a null effect. When only patients with atrial fibrillation were included, rivaroxaban was associated with higher rates of overall GIB than apixaban (HR, 1.40 [CI, 1.01 to 1.94]) or dabigatran (HR, 2.04 [CI, 1.17 to 3.55]). Dabigatran was associated with lower rates of upper GIB than rivaroxaban in both analyses.


LIMITATIONS - Unmeasured confounding and small subgroup analyses.


CONCLUSION - Rivaroxaban was associated with higher GIB rates than apixaban and dabigatran regardless of treatment indication.


PRIMARY FUNDING SOURCE - Icelandic Centre for Research and Landspítali–The National University Hospital of Iceland.


>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top